Financial News

Markets:

Overview

News

Currencies

International

Treasuries

Pfizer (NY:PFE)

25.41 UNCHANGED

Streaming Delayed Price Updated: 7:00 PM EDT, Aug 4, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Pfizer

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

S&P 500 Prints Fresh Record As Chips Rip And Hormuz Talks Crack The Oil Trade ↗

Today 4:01 EDT

Via Chartmill

Topics Stocks

Looking for the most active stocks in the S&P500 index on Tuesday? ↗

August 04, 2026

Via Chartmill

Pfizer Says Monthly GLP-1 Candidate Could Rival Tirzepatide on Weight Loss ↗

August 04, 2026

Pfizer stock rises after beating Q2 estimates and raising its 2026 revenue guidance to up to $62.5B. Get the key earnings takeaways.

Via Benzinga

BioNTech Q2 Earnings Call Highlights ↗

August 04, 2026

BioNTech (NASDAQ:BNTX) reported second-quarter 2026 revenue of €106 million, down from €261 million a year earlier, as lower U.S. demand for its COVID-19 vaccine weighed on results. The prior-year...

Via MarketBeat

Topics Earnings

Dow Jumps Over 700 Points; Pfizer Posts Upbeat Q2 Earnings ↗

August 04, 2026

Dow rises 1.35% with technology sector leading market gains. Pfizer beats Q2 earnings expectations. Oil down 4.2%, gold up 0.8%, European markets higher.

Via Benzinga

Topics Stocks

Pfizer (NYSE:PFE) Beats Q2 Expectations and Raises 2026 Revenue Guidance ↗

August 04, 2026

Via Chartmill

Pfizer Hikes 2026 Sales Outlook By $500 Million On Second-Quarter Beat ↗

August 04, 2026

Pfizer stock inched higher early Tuesday on a solid second-quarter report that included a sales guidance boost.

Via Investor's Business Daily

Pfizer’s (NYSE:PFE) Q2 CY2026: Beats On Revenue

August 04, 2026

Global pharmaceutical company Pfizer (NYSE:PFE) reported Q2 CY2026 results beating Wall Street’s revenue expectations, with sales up 2.6% year on year to $15...

Via StockStory

Pfizer Reports Second-Quarter Results And Raises Midpoint of 2026 Revenue Guidance

August 04, 2026

From Pfizer Inc.

Via Business Wire

Caterpillar, Pfizer and 3 Stocks to Watch Heading Into Tuesday ↗

August 04, 2026

Stocks to watch today: Caterpillar, Palantir, McDonald's, Snap, Pfizer. Positive Q2 earnings reported and upbeat sales guidance issued.

Via Benzinga

Pfizer Gears Up For Q2 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts ↗

August 04, 2026

Pfizer (PFE) will release Q2 earnings on Aug. 4, expected to report lower EPS of 68 cents and revenue at $14.39B. Stock rose 0.1% on Monday.

Via Benzinga

SpaceX Could Swing $204 Billion After Earnings ↗

August 03, 2026

Earnings set for tight window on Tuesday, Benzinga Pro data show options pricing 3.19% move for Pfizer and 5.15% for Amgen and Gilead Sciences.

Via Benzinga

Pfizer's Stock Has Been a Dud Over the Past 5 Years, but Is It Still Worth Buying for Its 6.9% Yield? ↗

August 03, 2026

The stock's yield is more than six times the S&P 500 average.

Via The Motley Fool

Topics Stocks

Pfizer (PFE) Q2 Earnings: What To Expect

August 02, 2026

Global pharmaceutical company Pfizer (NYSE:PFE) will be reporting earnings this Tuesday before market hours. Here’s what to expect. Pfizer beat analysts’ rev...

Via StockStory

Bristol Myers Squibb Isn't Nearly as Cheap as It Looks -- Here's the 1 Thing That Could Change That ↗

August 01, 2026

Bristol Myers Squibb's P/E ratio is below the industry average, but you have to take this key fact into consideration before buying it.

Via The Motley Fool

Topics Intellectual Property

Pfizer Yields 6.8%, Trades at 8.5X Earnings, and Has a Promising Late-Stage Weight Loss Drug. Why Are So Many Investors Still Ignoring the Stock? ↗

July 31, 2026

There is more to this stock than meets the eye.

Via The Motley Fool

Topics Intellectual Property

Regeneron Pharmaceuticals Q2 Earnings Call Highlights ↗

July 30, 2026

Regeneron Pharmaceuticals (NASDAQ:REGN) reported second-quarter revenue growth of 17% from a year earlier to $4.3 billion, supported by continued strength in Dupixent, EYLEA HD and Libtayo. Non-GAAP...

Via MarketBeat

Topics ETFs Earnings

Regency Centers Q2 Earnings Call Highlights ↗

July 30, 2026

Regency Centers (NASDAQ:REG) reported second-quarter operating momentum marked by higher occupancy, rent growth and an expanded development pipeline, prompting the grocery-anchored shopping center...

Via MarketBeat

Topics ETFs Earnings

Pfizer Prepares Global Regulatory Litfulo Filings Following Skin Pigment Improvements In Late-Stage Trials ↗

July 30, 2026

Pfizer reports Phase 3 data for LITFULO in treating nonsegmental vitiligo and plans to submit global regulatory filings.

Via Benzinga

Pfizer Announces Positive Topline Phase 3 Results for LITFULO in Patients with Nonsegmental Vitiligo

July 30, 2026

From Pfizer Inc.

Via Business Wire

What Health Experts Want You to Know About Pneumococcal Pneumonia

July 30, 2026

Via StatePoint Media

European Commission Authorizes Pfizer and BioNTech XFG-adapted COVID-19 Vaccine in the European Union

July 29, 2026

From Pfizer Inc.

Via Business Wire

AbbVie Has Raised Its Dividend for 53 Straight Years and Still Looks Attractively Valued. Is This Dividend King the Smartest Buy in Healthcare Right Now? ↗

July 29, 2026

AbbVie still looks like a compelling buy at its all-time high.

Via The Motley Fool

Topics Intellectual Property

Global Oral Contraceptive Drugs Market Growing at 7.3% CAGR Through 2034 ↗

July 29, 2026

According to a new report from Intel Market Research, the global Oral Contraceptive Drugs market was valued at USD 12.9 billion in 2024 and is projected to

Via Talk Markets

GOP Congressman Slams JD Vance's Silence Over CDC's $1.24 Billion Pfizer COVID Vaccine Contracts: 'Why Isn’t He Speaking Out' ↗

July 27, 2026

Rep. Thomas Massie questions JD Vance's silence after the Trump CDC established a $1.24 Billion Pfizer COVID-19 vaccine contract.

Via Benzinga

Topics Government

Generic Pharmaceuticals Stocks Q1 Highlights: Viatris (NASDAQ:VTRS)

July 26, 2026

The end of the earnings season is always a good time to take a step back and see who shined (and who didn’t). Let’s take a look at how generic pharmaceutical...

Via StockStory

Topics Artificial Intelligence Intellectual Property

3 Absurdly Cheap Dividend Stocks to Buy Before August ↗

July 26, 2026

Far from "yield traps," these high-yield dividend stocks represent good value at current prices.

Via The Motley Fool

Topics Artificial Intelligence

Pfizer's Dividend Yield Looks Almost Too Good. Here's Why Management Isn't Worried. ↗

July 25, 2026

Pfizer has a 6.8% yield at a time when the market's yield is roughly 1%: Is there something wrong?

Via The Motley Fool

3 Healthcare Stocks We Keep Off Our Radar

July 24, 2026

Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Players catalyzing medical advancements have...

Via StockStory

BioNTech's Next Act Has Nothing to Do With COVID. Here's the $500 Billion Market Some Investors Are Ignoring ↗

July 23, 2026

Could it become as successful in this niche as it was in the coronavirus vaccine market?

Via The Motley Fool

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Financial News

Pfizer (NY:PFE)

All News about Pfizer

Popular Pages